Leerink Swann Upgrades Medicines Company To Outperform

Analysts at Leerink Swann upgraded

from Market Perform to Outperform. The price target for Medicines Company has been raised from $24 to $31. Medicines Company shares have declined 36.78% over the past 52 weeks, while the S&P 500 index has gained 9.63% in the same period. Medicines Company's shares fell 1.52% to close at $24.70 yesterday.